Blue Sail Medical Co., Ltd. Class A

As of June 30, 2026, Blue Sail Medical Co., Ltd. Class A carries a market capitalization of 5.12B, placing it among publicly traded companies globally. Its enterprise value stands at 9.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Blue Sail Medical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 26, 2026.

As of June 30, 2026, Blue Sail Medical Co., Ltd. Class A has 1.01B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.78, and the price-to-book ratio stands at 0.72.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.09B versus a market cap of 5.12B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Blue Sail Medical Co., Ltd. Class A maintains a current ratio of 0.91, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 32.29, indicating elevated leverage, while an interest coverage ratio of -0.63 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Blue Sail Medical Co., Ltd. Class A posted a negative return on equity (ROE) of -7.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.59, reflecting losses generated across the asset base. The company generates approximately 732,985.44 in revenue per employee across its workforce of 8,957.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.33 indicates how many times Blue Sail Medical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Blue Sail Medical Co., Ltd. Class A recorded 269.91M in income tax expense. The company reported a pretax loss of -240.78M and -589.10M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Blue Sail Medical Co., Ltd. Class A's stock has declined approximately 0.70% over the past 52 weeks. The 50-day moving average sits at 6.06, while the 200-day moving average is 6.29.

Over the twelve months ended June 30, 2026, Blue Sail Medical Co., Ltd. Class A generated 6.57B in revenue and converted that into -589.10M in net income, yielding earnings per share of -0.51. EBITDA reached -158.28M, while operating income came in at 456.18M.

As of June 30, 2026, Blue Sail Medical Co., Ltd. Class A holds 1.48B in cash and equivalents against 3.07B in total debt, resulting in a net debt position of -9.57M. Total book value stands at 7.13B, with working capital of -454.50M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Blue Sail Medical Co., Ltd. Class A posted a gross margin of 23.97, reflecting its pricing power and cost economics. The operating margin of 6.95 and net profit margin of -8.97 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Blue Sail Medical Co., Ltd. Class A paid dividends of 0.27 per share. The dividend payout ratio of -62.72 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 22.96, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Blue Sail Medical Co., Ltd. Class A shareholders.

Blue Sail Medical Co., Ltd. Class A's most recent stock split took place on May 17, 2016 with a 1:2 split ratio.

As of June 30, 2026, Blue Sail Medical Co., Ltd. Class A has an Altman Z-Score of 1.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.